Selected for the Strategic Core Technology Advancement Program ("Go-Tech") of the Ministry of Economy, Trade and Industry (METI), Government of Japan

AMS Planning, Inc. ("AMS"), a Hokkaido University-certified nuclear medicine infrastructure startup, today announced that it has established a non-dilutive capital framework to execute a ¥100 million (approximately US$0.7 million) technology development program through a combination of its selection as a funding candidate under Japan's Strategic Core Technology Advancement Program ("Go-Tech") and strategic financing from financial institutions.
Building on its US$2.2 million cumulative equity financing achieved through its May 2025 Pre-Series A round, AMS has now established a non-dilutive capital framework to execute a US$0.7 million technology development program, bringing the company's total capital base supporting growth initiatives to approximately US$3.0 million, without requiring additional equity issuance.

A Disciplined and Capital-Efficient Growth Strategy
AMS continues to pursue a disciplined financing strategy that balances innovation, financial sustainability, and long-term value creation.

Recognition Through Japan's Go-Tech Innovation Program
The Strategic Core Technology Advancement Program ("Go-Tech") is one of Japan's flagship programs supporting small and medium-sized enterprises developing innovative technologies with strong commercialization potential.
AMS has been selected as a funding candidate under the program following a highly competitive evaluation process. Final grant approval remains subject to completion of the government's formal grant award procedures.
https://www.kanto.meti.go.jp/seisaku/sapoin/r8fy_go-tech_saitaku1.html
The project supports the advancement of AMS's proprietary radioisotope filtration technologies and related infrastructure designed to improve safety, operational efficiency, and accessibility in nuclear medicine.

Program Scope

• Development of next-generation products and prototypes
• Technical validation with healthcare and clinical institutions
• Expansion of the company's intellectual property portfolio
• Recruitment of key engineering and technical personnel
• Commercialization readiness and manufacturing preparation

These activities will further strengthen the technological foundation of AMS's nuclear medicine infrastructure platform.

International Business Development
Separately from the Go-Tech project, AMS continues to expand relationships with hospitals, industry partners, and research institutions in international markets, including the United States and Germany, as part of its long-term global business development strategy.

CEO Comment
Yuichiro Sugawara, Founder and CEO of AMS, said:
"Establishing a non-dilutive capital framework to execute this technology development program marks another important milestone for AMS.
Following our successful Pre-Series A financing in 2025, we have strengthened our ability to advance innovation while preserving shareholder value through a disciplined capital strategy. We are honored to have been selected as a funding candidate under Japan's Go-Tech Program and sincerely appreciate the confidence shown by government organizations and our financial partners.
This program will accelerate the development of technologies that improve safety, operational efficiency, and patient access in nuclear medicine, laying the foundation for the next generation of nuclear medicine infrastructure."

About AMS
AMS Planning, Inc. is a venture-backed nuclear medicine infrastructure company developing technologies that remove operational barriers to radiopharmaceutical therapies and enable broader access to nuclear medicine worldwide.
Leveraging advanced radioisotope decontamination technologies developed in Japan's nuclear sector, AMS has developed the world's first filtration system designed to rapidly and safely remove radioactive isotopes from medical biowaste. Already deployed at leading hospitals in Japan, the technology helps reduce infrastructure barriers associated with radiopharmaceutical therapies while improving operational efficiency and workplace safety.
In addition to its engineering solutions, AMS is developing a broader portfolio of technologies supporting the continued advancement of nuclear medicine and theranostics.
For more information, please visit: https://www.ams-plan.com/

Media Contact: AMS Planning, Inc.
Website: https://www.ams-plan.com
Email: info@ams-plan.com